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Valproic acid (VPA) is a widely used anticonvulsant and mood-stabilizing drug whose use is often associated with drug-induced
weight gain. Treatment with VPA has been shown to upregulateWfs1 expression in vitro. Aim of the present study was to compare
the effect of chronic VPA treatment in wild type (WT) and Wfs1 knockout (KO) mice on hepatic gene expression profile. Wild
type,Wfs1 heterozygous, and homozygous mice were treated with VPA for three months (300mg/kg i.p. daily) and gene expression
profiles in liver were evaluated using Affymetrix Mouse GeneChip 1.0 ST array. We identified 42 genes affected byWfs1 genotype,
10 genes regulated by VPA treatment, and 9 genes whose regulation by VPA was dependent on genotype. Among the genes that
were regulated differentially by VPA depending on genotype was peroxisome proliferator-activated receptor delta (Ppard), whose
expression was upregulated in response to VPA treatment in WT, but not in Wfs1 KO mice. Thus, regulation of Ppard by VPA is
dependent onWfs1 genotype.
1. Introduction
Valproic acid (VPA) is a widely used mood stabilizer and
anticonvulsant [1]. In addition to VPA’s effect of alleviating
mania in the treatment of bipolar disorder (BD) there are
several secondary metabolic side effects associated with
VPA treatment, namely, a higher risk of developing insulin
resistance and weight gain [2].Weight gain has been reported
nearly in half of the patients using VPA as a treatment
[3]. In the case of BD patients, drug-induced weight gain
is particularly noteworthy since overweight and several
other metabolic disturbances are more common among
people with BD compared to the general population [4].
The mechanism of VPA treatment-induced weight gain is
unknown.
Impaired endoplasmic reticulum (ER) stress response
was proposed to be associated with BD [5]. X box binding
protein (XBP1) is a transcription factor of the ER stress
response pathway. A mutation in this gene (−116C/G) is
associated with bipolar disorder in the Japanese population
[6] andXBP1 expression is reduced in patients with BD [7, 8].
Wolframin (WFS1) is one of the genes that is induced in
response to ER stress via XBP1 [9]. It has been shown that
mood stabilizers lithium and VPA facilitate the ER stress
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response [10] and VPA inducesWFS1 expression in vitro [11].
VPA has also been shown to regulate the expression of other
members of the ER stress pathway in vitro [12, 13] and in vivo
[14].
Wfs1 is a 890 amino acid long transmembrane protein
located in the ER. Lack of WFS1 function results in impaired
ER stress response and apoptosis [9, 15–17]. Homozygous
mutations in theWFS1 gene result in a rare disease—Wolfram
syndrome that is characterized by early-onset diabetes melli-
tus, progressive optic atrophy, diabetes insipidus, and deafness
[18, 19]. The frequency of heterozygous carriers of mutations
in the WFS1 gene is remarkably high—1% of the general
population [20] and heterozygosity for the WFS1 mutations
has been reported to be a significant risk factor for psychiatric
illnesses [20, 21]. Mutations in the WFS1 gene have been
reported in patients with bipolar disorder, major depression,
schizophrenia, and suicide victims without Wolfram syn-
drome [18, 19, 22–31]. There are conflicting reports on the
connection between the WFS1 gene and bipolar disorder.
Kato et al. found no association of WFS1 polymorphisms
and expression level in postmortem tissue of Japanese BD
patients [32], and similar results were found in another study
in Japanese patients [27]. Nevertheless, a recentmeta-analysis
of genome-wide expression studies on BD revealed WFS1 to
be significantly correlated with BD in the prefrontal cortex
[33].Wfs1KOmicewere suggested as a possible animalmodel
of BD [34]. We therefore hypothesize that the lack of Wfs1
function in Wfs1 KO mice mimics to a certain extent the
aberrant ER stress response observed in some patients with
BD.
Wfs1 KO mice exhibit impaired glucose tolerance and
they are significantly smaller than their wild type littermates
despite elevated growth hormone (GH) and insulin-like
growth factor (IGF-1) levels [35]. In our previous study we
found that acute treatment with valproic acid normalizes
glucose tolerance inWfs1mutantmice [36].This effect ofVPA
was not mediated via increased insulin secretion, since the
effect of VPA was also observed in mice with streptozotocin-
induced type 1 diabetes. Thus, acute VPA treatment mimics
and potentiates the effect of insulin in diabetic mice [36].
This study was conceived to investigate the effect of chronic
administration of VPA on glucose tolerance and also on the
gene expression in a metabolically relevant tissue. The liver
was chosen as this organ plays an important role in the
effect of insulin on the regulation of glucose metabolism, and
also the expression level of Wfs1 is substantial in the liver
[37].
As male Wfs1 KO mice exhibit stronger phenotype than
female mice and Wfs1 KO mice are smaller than wild type
littermates the study was done on male young mice and
a three-month long treatment was chosen to evaluate the
possible effect of chronic VPA treatment on the growth of
Wfs1mutant mice.
By comparing drug-induced changes of gene expression
in wild type and Wfs1 KO mice we hoped to find the genes
that are potentially involved in the VPA treatment-induced
metabolic alterations seen in BD patients.
2. Materials and Methods
2.1. Animals. Mice were housed under standard laboratory
conditions on a 12 h light/dark cycle (lights on at 07:00 AM)
with free access to regular chow diet (R70 Lantma¨nnen,
Sweden) andwater. All animal experiments in this study were
performed in accordance with the European Communities
Directive (86/609/EEC) and a permit (number 39, October
7, 2005) from the Estonian National Board of Animal Exper-
iments. Male wild type and Wfs1 mutant mice were used
throughout this study; they were 4 to 6 weeks old at the
beginning of the experiment. Mice were treated for three
months with valproic acid (VPA, Sigma Aldrich, 300mg/kg
i.p. daily) or vehicle (0.9% saline 10 mL/kg i.p. daily). Dose
of VPA for chronic study was chosen as described previously
[14]. A glucose tolerance test (2 g/kg i.p.) was performed 24
hours after the last VPA injection and mice were killed 24
hours after the glucose tolerance test. The liver was dissected
out, snap frozen in liquid nitrogen, and stored at −80∘C until
further analysis. Mice were 16 to 18 weeks old when killed.
Each experimental group consisted of 8 animals. Generation
ofWfs1mutant mice was described previously [35].
2.2. Glucose Tolerance Test. Mice were kept in their home
cages with free access to food and water. Food was removed
60 minutes prior to the experiment. Basal levels of blood
glucose were determined from the tail vein; thereafter mice
were injected with glucose (2 g/kg, i.p.) and blood glucose
levels were determined using a hand held glucose meter
(Accu-CheckGo, Roche,Mannheim,Germany) at 30, 60, and
90 minutes following glucose injection.
2.3. Preparation of RNA andMicroarray Hybridization. Total
liver RNA was extracted using Trizol reagent (Ambion, Life
Technologies). Integrity of total RNA was evaluated using
the Agilent Bioanalyzer 2100 system (Agilent Technologies,
CA, USA) and was within RNA integrity number (RIN) 7
to 9 and thus considered suitable for further processing.
300 nanograms of total RNA were processed to produce
fragmented biotin-labeled cRNA using the Ambion WT
expression kit according tomanufacturer’s instructions. Sam-
ples were hybridized Affymetrix GeneChip Mouse Gene 1.0
ST arrays and quantified. Images were processed and cell
intensity files (CEL files) were generated in the GeneChip
Command Console Software (Affymetrix). CEL files were
processed using Expression Console v.1.1.2800.28061 to yield
RMA summarized Log2 transformed expression values for
probesets (CHP files). Normalized expression data (CHP
files) were analysed using ANOVA in R (genotype x
treatment) using R package Bioconductor. The data dis-
cussed in this publication have been deposited in NCBI’s
Gene Expression Omnibus [38] and are accessible through
GEO Series accession number GSE55143 (http://www.ncbi
.nlm.nih.gov/geo/query/acc.cgi?acc=GSE55143).
2.4. Microarray Data Analysis. Raw data from gene chips
were processed with the RMA method, which involves
quantile normalization. Two-way ANOVAwas performed on
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the normalized expression data using R software. A gene list
was created that contained probesets with 𝑃 < 0.001 for
genotype effects. Only genes showing significantly different
changes greater than 2-fold were considered for effect of
genotype. For the effect of VPA treatment a 𝑃 value of 0.001
was used as a cutoff. Given the small number of genes for
which genotype-treatment interaction was established, a 𝑃
value of 0.003 was used as a cutoff.
Differently expressed genes were annotated to find
the molecular function using the web-based international
database Mouse Genome Informatics Gene Ontology (MGI
GO) that includes genetic, biological, and genomic infor-
mation of laboratory mouse and also the UniProt Knowl-
edgebase (UniProtKB/Swiss-Prot) that holds the functional
information of known proteins.
2.5. Gene Expression Studieswith qRT-PCRAnalysis. For con-
firming differences in expression of genes of interest found
on gene chip, quantitative real-time PCR (qRT-PCR) analysis
was used. For that purpose, the ABI PRISM 7900HT Fast
Real-Time PCR System equipment (PE Applied Biosystems,
USA) and the ABI PRISM 7900 SDS 2.2.2 Software were
used. In all gene expression experiments, cytoplasmic 𝛽-
actin (Actb) (VIC/MGB Probe, Primer Limited) was used
as the endogenous reference gene (PE Applied Biosystems,
USA), All reactions were performed using the TaqMan
Gene Expression Master Mix (PE Applied Biosystems, USA)
and the TaqMan Gene Expression Assays (FAM) according
to the instructions of the equipment and reagent manu-
facturers. All samples to be compared were run in the
same experiment and every reaction was run in quadru-
plicate. The amount of the target gene was compared to
the housekeeper gene by means of the 2−ΔCT method [39].
The following TaqMan Gene Expression Assays (FAM) were
used: Ppard (Mm00803184 m1); Fmo2 (Mm0049019 m1);
Sult3a1 (Mm00491057 m1); Lepr (Mm0040181 m1); Wfs1
(Mm01220326 m1).
2.6. Statistics. Data are presented as means ± SEM and
were compared by two-way analysis of variance (ANOVA,
treatment and genotype as the independent factors) followed
by Tukey’s post hoc test. A 𝑃 value of <0.05 was considered
statistically significant. Statistical analysis was performed
using STATISTICAversion 9 (StatSoftLtd., Bedford,UK) and
GraphPad Prism version 5 software (GraphPad Software Inc.,
San Diego, CA, USA).
3. Results
3.1. Description of Wfs1 KO mice. To determine the effect of
VPA treatment on growth, the weight of WT, Wfs1 HZ, and
Wfs1KOmice was recorded weekly for 14 weeks. At the age of
16 weeks, homozygousWfs1KOmice had a remarkably lower
mean body weight than wild type (WT) or heterozygous
(HZ) mice (𝐹(2, 35) = 7.97; 𝑃 = 0.0014) (Figure 1). There
were noticeably different growth rates between the genotypes
starting from 8th to 9th week of age, when the growth of
Wfs1 KO was retarded, while the body weight of WT and HZ
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Figure 1: Body weight of male WT and Wfs1 mutant mice. At the
age of 16 months, Wfs1 KO (red circles) had lower body weight
than WT (black circles) or heterozygous HZ (green circles) mice
(𝐹(2, 35) = 7.97; 𝑃 = 0.0014). Growth rate of Wfs1 KO mice was
inhibited since 8th to 9th week of age, while the body weight of WT
and HZ continued to increase (𝐹(24, 420) = 9.65; 𝑃 < 0.000001).
Chronic administration of VPA for 3 months (300mg/kg/day, i.p.
solid symbols) had no effect on growth rate regardless of genotype
(𝐹(1, 35) = 1.43; 𝑃 = 0.2393). Data is presented as mean ± SEM
(𝑛 = 8).
continued to increase (𝐹(24, 420) = 9.65; 𝑃 < 0.000001).
Chronic administration of VPA for 3 months had no effect
on growth regardless of genotype, confirmed by Tukey’s HSD
(𝐹(1, 35) = 1.43; 𝑃 = 0.2393).
3.2. Glucose Tolerance Test after Chronic VPA Treatment.
Basal blood glucose levels of saline treated mice were slightly
but significantly elevated in the KO group as compared to
the WT or HZ group (𝐹(2, 21) = 10.03; 𝑃 = 0.00088).
Administration of glucose (2 g/kg i.p.) induced a rise in
blood glucose levels with a peak at 30min following glucose
administration in all genotypes (Figure 2(a)); this increase
was the highest in Wfs1 KO mice (𝐹(2, 21) = 75.71; 𝑃 =
0.000001). Tukey’s HSD test confirmed peak blood glucose
levels of the KO group being significantly higher compared
to the WT or HZ group (𝑃 = 0.00014); also blood glucose
levels in the homozygous group were higher than in WT
(𝑃 = 0.026).
Chronic administration of VPA had no effect on the basal
blood glucose levels regardless of genotype (𝐹(1, 43) = 0.52;
𝑃 = 0.475) but resulted in an increase of peak blood glucose
concentration at 30min in WT but not in Wfs1 HZ or KO
mice (𝐹(1, 43) = 17.31; 𝑃 = 0.00015). Tukey’s HSD test
confirmed peak blood glucose levels of VPA treatedWTmice
being significantly higher than in saline treated WT mice
(𝑃 = 0.0014). VPA had no effect on peak blood glucose
concentration in Wfs1 KO or HZ mice. However, there was
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Figure 2: Glucose tolerance test in maleWT andWfs1mutant mice after 3-month VPA treatment (300mg/kg/day). (a) Time course of blood
glucose levels following glucose challenge (2 g/kg, i.p.). Blood glucose was measured from tail vein immediately before and 30, 60, and 90
minutes following glucose administration. VPA treatment (solid circles) had no effect on glucose tolerance inWfs1KOorWfs1HZmice when
compared to respective vehicle group (0.9% saline, 10mL/kg, i.p., open circles). (b) Area under the curve of glucose time curves. Two-way
ANOVA followed by Tukey’s HSD test (∗∗∗𝑃 < 0.001 versus (+/+SAL); §§§𝑃 < 0.001 versus (+/+VPA); $𝑃 < 0.05 versus (−/−SAL)). Data is
presented as mean ± SEM (𝑛 = 8).
no statistically significant effect of VPA treatment-genotype
interaction (𝐹(2, 43) = 2.867; 𝑃 = 0.0677).
Wfs1 KOmice had largest area under the curve (AUC) of
IPGTT test (𝐹(2, 43) = 52.81; 𝑃 = 0.000001), Tukey’s HSD
test confirmed Wfs1 KO mice having greater AUC than WT
(𝑃 = 0.00014) or HZ mice (𝑃 = 0.00068). There was no
difference of AUC values between WT and Wfs1 HZ group.
Chronic administration of VPA resulted in an increase of
AUC (𝐹(1, 43) = 14.16; 𝑃 = 0.0005); Tukey’s HSD test
confirmed VPA treated Wfs1 KO mice having greater AUC
than saline treated Wfs1 KO mice (𝑃 = 0.025). Chronic
treatment with VPA had no effect on AUC values in WT
(𝑃 = 0.099) andWfs1HZ mice (𝑃 = 0.99).
3.3. Hepatic Gene Transcription Profile. Total RNA was
extracted from the liver of male mice and analysed using
the Affymetrix GeneChip Mouse Gene 1.0 ST Array. Quality
of microarray hybridization and distribution of raw signal
intensity across microarray chips was uniform across 48
samples (data not shown).
We did not see a decrease in expression of Wfs1 gene in
Wfs1 KO mice using gene chip array. Affymetrix GeneChip
Mouse Gene 1.0 ST Array has a probe for every exon of the
gene. Our Wfs1 mutant mouse was created by invalidating
just two exons (7 and 8) of the Wfs1 gene; the remaining six
exons of this gene are intact in Wfs1 KO mice. Thus, we did
not detect decreased expression levels of Wfs1 gene in Wfs1
KO mice using these arrays. However, exon specific analysis
revealed lower expression of exons 7 and 8 of Wfs1 gene in
Wfs1 KOmice (data not shown).
We identified large number of genes that are differentially
expressed depending on Wfs1 genotype. There were 23
upregulated and 19 downregulated genes in Wfs1 KO mice
as compared to WT mice (Table 1). Ten genes were regulated
by VPA treatment (Table 2) and further 9 genes showed an
interaction between genotype and VPA treatment (Table 3).
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Table 1: List of genes whose expression in mouse liver is regulated byWfs1 genotype as measured by Affymetrix GeneChip Mouse Gene 1.0
ST Array.
Probeset ID 𝑃 value 𝑄-value Fold change Gene Gene description
Upregulated inWfs1 KOmice
10362464 6.32𝐸 − 05 0.028767 131.3 Sult3a1 Sulfotransferase family 3A, member 1
10359593 4.94𝐸 − 06 0.008869 112.2 Fmo3 Flavin containing monooxygenase 3
10551209 3.81𝐸 − 04 0.055722 37.6 Cyp2b13 Cytochrome P450, family 2, subfamily b, polypeptide 13
10465726 8.82𝐸 − 06 0.011336 14.0 BC014805 cDNA sequence BC014805
10561162 7.93𝐸 − 05 0.031687 10.3 Cyp2a22 Cytochrome P450, family 2, subfamily a, polypeptide 22
10465734 3.50𝐸 − 06 0.008869 9.8 AB056442 cDNA sequence AB056442
10500570 1.07𝐸 − 04 0.035569 6.3 Hao2 Hydroxyacid oxidase 2
10506301 1.46𝐸 − 05 0.013481 5.2 Lepr Leptin receptor
10425822 7.17𝐸 − 04 0.080582 5.0 Pnpla3 Patatin-like phospholipase domain containing 3
10520622 5.54𝐸 − 15 1.79𝐸 − 10 4.8 Abhd1 Abhydrolase domain containing 1
10468239 4.10𝐸 − 04 0.05785 4.4 Cyp17a1 Cytochrome P450, family 17, subfamily a, polypeptide 1
10359582 9.44𝐸 − 07 0.004726 4.4 Fmo2 Flavin containing monooxygenase 2
10397158 1.19𝐸 − 04 0.037527 3.5 Acot3 acyl-CoA thioesterase 3
10574027 7.39𝐸 − 04 0.081551 3.5 Mt1 Metallothionein 1
10533401 7.42𝐸 − 04 0.081551 2.9 Cux2 Cut-like homeobox 2
10350733 3.59𝐸 − 04 0.053424 2.8 Rgs16 Regulator of G-protein signaling 16
10465740 2.81𝐸 − 04 0.049115 2.4 Gm6192 Predicted gene 6192
10362472 2.97𝐸 − 04 0.050271 2.2 Rsph4a Radial spoke head 4 homolog A (Chlamydomonas)
10467372 6.13𝐸 − 05 0.028301 2.1 Cyp2c38 Cytochrome P450, family 2, subfamily c, polypeptide 38
10519527 1.29𝐸 − 04 0.038113 2.1 Abcb1a ATP-binding cassette, sub-family B (MDR/TAP), member 1A
10529977 3.97𝐸 − 06 0.008869 2.1 Ppargc1a Peroxisome proliferative activated receptor, gamma, coactivator1 alpha
10548996 4.56𝐸 − 04 0.062377 2.0 Slco1a4 Solute carrier organic anion transporter family, member 1a4
10515187 6.50𝐸 − 04 0.07526 2.0 Cyp4a14 Cytochrome P450, family 4, subfamily a, polypeptide 14
Downregulated inWfs1 KOmice
10571560 1.68𝐸 − 04 0.03933 2.0 Mtnr1a Melatonin receptor 1A
10597875 1.21𝐸 − 05 0.01261 2.0 Cyp8b1 Cytochrome P450, family 8, subfamily b, polypeptide 1
10454015 1.42𝐸 − 05 0.01348 2.0 Ttc39c Tetratricopeptide repeat domain 39C
10502214 5.25𝐸 − 06 0.00892 2.2 Cyp2u1 Cytochrome P450, family 2, subfamily u, polypeptide 1
10498584 9.12𝐸 − 06 0.01133 2.4 Rarres1 Retinoic acid receptor responder (tazarotene induced) 1
10482528 2.47𝐸 − 05 0.01781 2.5 Neb Nebulin
10579649 4.58𝐸 − 05 0.02463 2.6 Cib3 Calcium and integrin binding family member 3
10415279 2.82𝐸 − 05 0.01939 2.6 Fitm1 Fat storage-inducing transmembrane protein 1
10602372 2.33𝐸 − 06 0.00740 2.6 Alas2 Aminolevulinic acid synthase 2, erythroid
10548931 1.53𝐸 − 04 0.03829 2.7 Slc15a5 Solute carrier family 15, member 5
10500545 1.25𝐸 − 04 0.03811 2.8 Hsd3b5 Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroiddelta-isomerase 5
10507152 2.10𝐸 − 04 0.04265 3.0 Cyp4a12b Cytochrome P450, family 4, subfamily a, polypeptide 12B
10352439 4.13𝐸 − 06 0.00886 3.1 Susd4 Sushi domain containing 4
10507143 1.99𝐸 − 04 0.04099 3.1 Cyp4a12a Cytochrome P450, family 4, subfamily a, polypeptide 12a
10513538 9.25𝐸 − 05 0.03306 3.1 Mup21 Major urinary protein 21
10545877 4.37𝐸 − 07 0.00353 3.5 Nat8 N-Acetyltransferase 8 (GCN5-related, putative)
10497381 3.81𝐸 − 07 0.00353 3.9 Cyp7b1 Cytochrome P450, family 7, subfamily b, polypeptide 1
10545874 5.38𝐸 − 05 0.02674 4.6 Cml5 Camello-like 5
10463551 1.06𝐸 − 07 0.00171 6.4 Elovl3 Elongation of very long chain fatty acids (FEN1/Elo2,SUR4/Elo3, yeast)-like 3
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Table 2: List of genes whose expression in mouse liver is regulated by chronic VPA treatment as measured by Affymetrix GeneChip Mouse
Gene 1.0 ST Array.
Probeset ID 𝑃 value 𝑄-value Fold change Gene symbol Gene description
10454353 1.81𝐸 − 04 0.66000 1.59 S100a10 S100 calcium binding protein A10 (calpactin)
10425421 2.87𝐸 − 04 0.738978 1.46 Pcna Proliferating cell nuclear antigen
10493995 1.60𝐸 − 04 0.660001 1.46 Fam83f Family with sequence similarity 83, member F
10518069 9.94𝐸 − 04 0.754625 1.46 Efhd2 EF hand domain containing 2
10383545 3.52𝐸 − 04 0.754625 1.45 Pcna Proliferating cell nuclear antigen
10487930 6.38𝐸 − 04 0.754625 1.36 Tbc1d19 TBC1 domain family, member 19
10461391 4.38𝐸 − 05 0.569567 1.35 Gpr39 // Lypd1 G protein-coupled receptor 39 // Ly6/Plaur domaincontaining 1
10521927 5.10𝐸 − 05 0.569567 1.35 E130311K13Rik RIKEN cDNA E130311K13 gene
10349401 4.74𝐸 − 04 0.754625 1.30 Mocos Molybdenum cofactor sulfurase
10498477 9.13𝐸 − 04 0.754625 1.26 Foxk2 Forkhead box K2
3.4. Confirmation of Selected Hits by qRT-PCR. The change in
expression levels of selected genes (Sult3a1, Fmo2, Lepr, and
Ppard)was verifiedwith qRT-PCR technique (Figure 3). qRT-
PCRdata showed similar expression levels asAffymetrix gene
chip analysis (Figure 3).
The expression level of Ppard was elevated by VPA
treatment (𝐹(1, 42) = 52.5; 𝑃 < 0.000001), and the effect
was dependent on genotype (𝐹(2, 42) = 8.66; 𝑃 = 0.0007)
as revealed by Affymetrix GeneChip data (Figure 3(a)). The
induction of Ppard expression by VPA was strongest in
WT mice and lowest in Wfs1 KO mice. Similar results
were obtained also by qRT-PCR analysis for effect of VPA
treatment (𝐹(1, 42) = 36.34; 𝑃 < 0.0000001) and treatment-
genotype interaction (𝐹(2, 42) = 10.8; 𝑃 = 0.0002,
Figure 3(b)).
Expression of Lepr was highly elevated in liver of Wfs1
KO mice in comparison to WT orWfs1 HZ mice (𝐹(2, 42) =
38.8; 𝑃 < 0.000001) as revealed by Affymetrix GeneChip
data (Figure 3(c)). The effect of genotype on Lepr expression
pattern was confirmed with qRT-PCR method (𝐹(2, 38) =
12.95; 𝑃 = 0.00005, Figure 3(d)). Two-way ANOVA revealed
also inhibitory effect of VPA on the expression of Lepr
according to Affymetrix GeneChip data (𝐹(1, 42) = 8.5;
𝑃 = 0.0057); however, such effect of VPA treatment was
not confirmed by qRT-PCR analysis, possibly due to a large
variation in Wfs1 KO VPA group in qRT-PCR analysis
(Figure 3(d)).
Expression level of Sult3a1 in liver of maleWfs1 KOmice
was much higher than in male Wfs1 HZ or male WT mice
(𝐹(2, 42) = 22.5; 𝑃 < 0.00001) as revealed by Affymetrix
gene chip, such finding was confirmed by qRT-PCR analysis
(𝐹(2, 37) = 6.34; 𝑃 = 0.004). In fact, the expression level of
Sult3a1 in WT mice was below detection limit by qRT-PCR
method. VPA treatment had no effect on expression level of
Sult3a1 (Figures 3(e) and 3(f)).
The expression level of Fmo2was dependent on genotype
and VPA treatment as revealed by Affymetrix gene chip
analysis (Figure 3(g)); its expression was higher in Wfs1 KO
as compared to WT mice (𝐹(2, 42) = 30.4; 𝑃 < 0.000001).
The expression of Fmo2was inhibited byVPA treatment in all
genotypes (𝐹(1, 42) = 16.5; 𝑃 = 0.0002). Similar results were
obtained also by qRT-PCR analysis for genotype (𝐹(2, 42) =
10.9; 𝑃 = 0.001) and VPA treatment (𝐹(1, 42) = 5.04; 𝑃 =
0.03, Figure 3(h)).
3.5. Regulation ofWfs1 Expression by VPA. qRT-PCR analysis
revealed that the expression level ofWfs1was elevated byVPA
treatment (𝐹(1, 41) = 7.72; 𝑃 = 0.0082); however, there was
no interaction of treatment withWfs1 genotype (Figure 4(a)).
As expected, the expression level of Wfs1 was dependent
on genotype (𝐹(2, 41) = 15.38; 𝑃 < 0.0001); expression
level of Wfs1 in heterozygous mutant mice was reduced to
54% in comparison with wild type mice (Figure 4(a)). The
expression level of Wfs1 was compared to expression level
of Ppard for possible interaction (expression of both genes
was measured by qRT-PCR); regression coefficient of linear
regression across all samples was 𝑅2 = 0.433 (𝑃 < 0.0001,
Figure 4(b)).
4. Discussion
The growth ofWfs1 KO mice was retarded compared to WT
or Wfs1 HZ animals, confirming the results of our previous
study [35]. Chronic treatment with VPA had no effect on
the growth rate (Figure 1). Interestingly, the growth of Wfs1
KO mice seems to be similar to that of WT mice until 8
weeks of age, but thereafter the growth ofWfs1KOmice slows
down, while WT and Wfs1 HZ mice continue to grow. The
mechanism of such age dependency is not known but could
be related to the sexual development of mice. We have shown
that acute administration of VPA improves glucose tolerance
of Wfs1 KO and HZ mice [36], thus we wanted to evaluate
the effect of chronic VPA administration in these mice.
Interestingly, chronic treatment with VPA had no effect on
basal blood glucose levels regardless of genotype (Figure 2).
However, chronic VPA treatment resulted in increased peak
glucose level during glucose tolerance test in WT mice and
VPA treated Wfs1 KO mice showed an increased area under
the curve during glucose tolerance test. Therefore, chronic
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Figure 3: Comparison of results from Affymetrix GeneChip Mouse Gene 1.0 ST Array and qRT-PCR analysis. qRT-PCR mRNA expression
is represented as the mean of quadruplicate per sample against the endogenous reference gene ACTB. (a) and (b) Ppard. Upregulation of
Ppard by valproic acid (VPA) is abolished by Wfs1 invalidation. (c) and (d) Lepr. Lepr is upregulated in Wfs1 KO mice. (e) and (f) Sult3a1.
Sult3a1 expression is increased inWfs1 KO mice while downregulated by VPA. (g) and (h) Fmo2. Fmo2 expression level is increased inWfs1
KOmice. All data are presented as means ± SEM (𝑛 = 8) and were compared by two-way analysis of variance (ANOVA) followed by Tukey’s
post hoc test (∗∗∗𝑃 < 0.001, ∗∗𝑃 < 0.01).
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Table 3: List of genes whose expression in mouse liver by chronic VPA treatment is dependent onWfs1 genotype as measured by Affymetrix
GeneChip Mouse Gene 1.0 ST Array.
Probeset ID 𝑃 value 𝑄-value Fold changes Gene symbol Gene description
10443332 1.1𝐸 − 04 0.99999 2.26 Ppard Peroxisome proliferator activator receptor delta
10409278 2.1𝐸 − 03 0.99999 2.17 Nfil3 Nuclear factor, interleukin 3, regulated
10417734 5.6𝐸 − 04 0.99999 2.03 Nr1d2 Nuclear receptor subfamily 1, group D, member 2
10514520 1.9𝐸 − 03 0.99999 1.58 Cyp2j9 Cytochrome P450, family 2, subfamily j, polypeptide 9
10535759 9.2𝐸 − 04 0.99999 1.32 Lnx2 Ligand of numb-protein X 2
10489694 1.9𝐸 − 03 0.99999 1.26 Zfp334 Zinc finger protein 334
10459353 1.3𝐸 − 03 0.99999 1.25 Fam38b Family with sequence similarity 38, member B
10351414 1.7𝐸 − 03 0.99999 1.20 Aldh9a1 Aldehyde dehydrogenase 9, subfamily A1
10473690 2.1𝐸 − 03 0.99999 1.18 Fnbp4 Formin binding protein 4
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Figure 4: qRT-PCR analysis ofWfs1 expression in hepatic tissue ofWT andWfs1mutant mice. qRT-PCRmRNA expression is represented as
the mean of quadruplicate per sample against the endogenous reference gene Actb. (a) Chronic treatment with valproic acid (VPA) induces
upregulation ofWfs1 expression (𝐹(1, 41) = 7.72; 𝑃 = 0.0082). Expression level ofWfs1 follows a gene-dose relationship withWfs1 genotype
(𝐹(2, 41) = 15.38; 𝑃 < 0.0001). All data are presented as means ± SEM (𝑛 = 8) and were compared by two-way analysis of variance (ANOVA).
(b) Relationship between the expression levels of Wfs1 and Ppard, linear regression across all data points 𝑅2 = 0.433 (𝑃 < 0.0001), and
expression levels of Ppard andWfs1 were measured using qRT-PCR, each point corresponds to one animal.
VPA seems to impair glucose tolerance of Wfs1 KO mice,
contrary to its acute effect.
We identified a number of genes that are differentially
expressed depending on Wfs1 genotype; a few of them are
regulated by VPA treatment. Animals were sacrificed 48
hours after last administration of valproic acid and it is
possible that drug treatment effects are normalized during
that time. Therefore, the genes showing persistent alteration
might be themost relevant ones.We identified 23 upregulated
and 19 downregulated genes inWfs1KOmice as compared to
WTmice (Table 1). Ten genes were altered by VPA treatment
(Table 2) and further 9 genes showed an interaction with
genotype and treatment (Table 3). The expression levels of
four genes were evaluated by qRT-PCR, and the twomethods
gave qualitatively similar results.
Many of the genes which were dependent on the Wfs1
genotype were functionally involved in oxidative processes,
including cytochromes, proteins that participate in electron
transport (Cyp2b13, Cyp2a22, Cyp17a1, Cyp2c38, Cyp4a14,
Cyp8b1, Cyp2u1, Cyp4a12b, and Cyp7b1), but also genes
for monooxygenases (Fmo3 and Fmo2) and organic anion
transporters (BC014805, AB056442, Abcb1a, and Slco1a4).
Some of the genes that were upregulated inWfs1KOmice are
involved in lipid metabolism (Hao2, Lepr, Pnpla3, Acot3, and
Ppargc1a). Also, some of the genes with decreased expression
in Wfs1 KO mice are involved in fatty acid metabolism
(Rarres1, Fitm1, Hsd3b5, and Elovl3). Interestingly, earlier
reports found Elovl3 to be upregulated in the liver in response
to subchronic [40] and single administration of VPA
[41].
Themain aim of this studywas to identify genes for which
the regulation by chronic VPA treatment is dependent on
the Wfs1 genotype. The three genes with the largest change
in expression were peroxisome proliferator activator receptor
delta (Ppard), interleukin-3 regulated nuclear factor (Nfil3),
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and nuclear receptor subfamily 1, groupD,member 2 (Nr1d2);
all of them are also linked with circadian rhythms [42].
In WT mice, VPA treatment caused an approximately 2-
fold increase in the expression of Ppard compared to vehicle
treatment. Such VPA induced upregulation of Ppard was
not detected in the liver of Wfs1 KO mice. These results
were verified by qRT-PCR analysis (Figures 3(a) and 3(b)).
Moreover, similar effect of VPA on Ppard expression was
observed earlier using in vitro bioassays in CHO and F9 cell
lines, where VPA activates Ppard gene expression [43, 44].
Thus, this finding is in agreement with earlier studies. Based
on PPAR reporter assays, VPA is classified as a “triple ppar-
alpha, -beta/delta, -gamma agonist” [45]. Ppard regulates the
expression of its target gene Pdk1 [46]; it is noteworthy that
the expression of this kinase was found to be upregulated in
response to VPA treatment in the liver slices [45].
PPARs are lipid-activated nuclear receptors with sev-
eral physiological functions, including control of fatty acid
metabolism in different tissues [47]. There are three different
subtypes of PPAR: PPAR𝛼, PPAR𝛽/𝛿 (PPARD), and PPAR𝛾,
each having different expression and biological activities
[48]. PPAR𝛼 is mainly expressed in tissues with intensive
𝛽-oxidation such as liver, kidneys, heart, skeletal muscles,
and intestine. It has been apparent from the experimental
and clinical trials that PPAR𝛼 is important for fatty acid
oxidation in the liver and heart [48]. PPAR𝛾 participates
in the proliferation and differentiation of adipocytes. It is
mainly expressed in the fat tissue, colon, endothelial cells,
and in the smooth muscle cells of blood vessels [48–50].
PPARD is widely expressed, but its physiological roles are
not as well understood as the ones of the other subtypes.
PPARD participates in the skin healing process and is also
important in controlling fatty acids oxidation in several
tissues, for example, muscle and fat tissue [47, 51]. Recently,
an intriguing role of PPARD in the regulation of hepatic
lipogenic pathway and fat use by muscle was identified.
Liver-specific PPARD activation increases fatty acid uptake
in the muscle via regulation of circulating fatty acids [52].
In addition, PPARD activation intensifies glycolysis and the
work of pentose phosphate shunt and promotes fatty acid
synthesis [48, 53].
Activation of PPARD has beneficial effect on body weight
and is proposed as treatment of type 2 diabetes [53]. Interest-
ingly, mutations in the PPARD gene are associated with BD
in the American population [54]; thus there might be also a
direct deficit of PPARD in patients with BD leading to the
development of metabolic syndrome. Activation of PPARD
in respective patients needs to be measured to test such a
hypothesis.
PPARD agonists are suggested as potential drugs in
the case of overweight and problems associated with that
[48, 55]. Moreover, Ppard interaction with hepatic AMPK
(phospho-AMP-activated protein kinase), PGC-1𝛼 (PPAR𝛼-
PPAR𝛾 coactivator), and lipin-1 refers to them as therapeutic
targets in the prevention of dyslipidemia [51]. It was recently
shown that Ppard agonist GW501516 prevents high fat diet
associated hyperglyceridemia [56]. GW501516 also restores
hepatic AMPK level, which is decreased with the over-
consumption of fat, and enhances lipin-1-PGC-1𝛼 dependent
pathway rising hepatic fatty acids oxidation [56]. Remark-
ably, Ppar𝛾c1a is one of the genes whose expression was
significantly higher in Wfs1 KO mice compared to WT mice
(Table 1).
It is unknownwhetherWfs1 is required for VPAmediated
induction of Ppard expression or lack of VPA effect in
Wfs1 KO mice is caused by some secondary changes in
these mice. Chronic VPA treatment results in an increase
of Wfs1 expression (Figure 4(a)). There seems to be a cor-
relation between the expression levels of Wfs1 and Ppard
(Figure 4(b)), further suggesting a regulatory link between
these two genes. However, molecular studies linking Wfs1
function with the regulation of Ppard are needed to definitely
answer this question. Also, it would be most interesting
to compare the regulation of PPARD in patients with and
without VPA treatment-induced weight gain. Based on our
results, we would speculate that PPARD is activated in
patients without drug induced weight gain, while its activity
is lower in obese patients receiving VPA.
It is hard to predict whether PPARD ligands will eventu-
ally be developed into FDA-approved drugs. Results of this
study suggest that these drugs must be evaluated for possible
interaction with valproic acid before use in patients.
5. Conclusions
GeneChip analysis showed that invalidation of theWfs1 gene
induces changes in liver transcriptome with impact on genes
involved in lipid and fatty acid metabolism. Expression of
Ppard in the liver is upregulated in response to chronic
treatment with valproic acid, such upregulation is absent
in Wfs1 KO mice. Importance of Ppard in the regulation
of metabolic processes is well recognized; thus the role of
such Wfs1-VPA interaction on the regulation of Ppard needs
further investigation.
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